Related Experiment Videos
Managing hematologic toxicities
1Sections of Medical Oncology and Palliative Medicine, at St. Vincent's Comprehensive Cancer Center, New York, NY 10001, USA. gcapo@salick.com
The Journal of Supportive Oncology
|August 28, 2004
Summary
Cancer chemotherapy can cause neutropenia, anemia, and thrombocytopenia. Evidence-based guidelines for cytokine growth factors and transfusion support are crucial for managing these hematologic toxicities effectively.
Area of Science:
- Oncology
- Hematology
Background:
- Cancer chemotherapy, particularly high-dose and dose-dense regimens, frequently leads to significant hematologic toxicities.
- Neutropenia, anemia, and thrombocytopenia are common and clinically significant side effects impacting patient outcomes.
Purpose of the Study:
- To provide evidence-based guidelines for managing chemotherapy-induced hematologic toxicities.
- To outline the appropriate use of cytokine growth factors and transfusion support.
Main Methods:
- Review of clinical trials and existing literature on hematologic toxicities.
- Analysis of the frequency, clinical significance, and management strategies for neutropenia, anemia, and thrombocytopenia.
Main Results:
- High-dose chemotherapy necessitates careful management of hematologic toxicities.
- Cytokine growth factors and transfusion support are essential for ameliorating these side effects.
Conclusions:
- Judicious use of cytokine support is critical for managing chemotherapy-induced hematologic toxicities.
- Understanding potential side effects of supportive agents and adhering to evidence-based guidelines ensures optimal patient care.